The German biotechnology sector, which witnessed two years of unprecedented investment, faced a stark contrast in 2022 as equity capital raised plummeted to €920 million. This marked a strong decline from the record highs of 2020, the inaugural year of the pandemic, which goes on to reflect the industry's evolving dynamics. In the aftermath of record-breaking investment in the previous years, 2022 presented a notable challenge for the German biotechnology industry. This dip was evenly distributed between private and listed companies.
The annual trend survey conducted by BIO Deutschland revealed a significant erosion of confidence among board members and company directors. Their satisfaction with the current business situation markedly decreased compared to previous years. The outlook for the coming year appears even more somber than during the 2008 financial crisis. Over half of the respondents cited the energy crisis as a negative factor affecting their business, while the impact of inflation was strongly felt by one-fifth and moderately felt by half.
The survey indicated a notable decline in companies planning to expand their workforce compared to the previous year. Moreover, there was a reduced willingness to increase spending on research and development (R&D). Despite these challenges, close to 90% of companies expressed a desire to investing in R&D. Such intentions support the drive towards innovation and research. The optimism that pervaded the industry in the last two years concerning the political climate saw a regression to pre-pandemic levels. A diminished 26% of respondents described their business situation as good in 2022, compared to 64% in 2021. Projections for an improved future business situation also saw a significant drop.
While challenges abound, the resilience of the German biotechnology industry remains evident in its commitment to R&D investment. Navigating uncertainties, the industry continues to adapt and strategize in the face of evolving economic and geopolitical landscapes.